Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Cardiology Reviews
  4. Volume 21, Issue 1
  5. Article
Volume 21, Issue 1
  • ISSN: 1573-403X
  • E-ISSN: 1875-6557

Abstract

Heart failure with preserved ejection fraction (HFpEF) includes almost half of heart failure cases typified by a specific clinical syndrome. Despite diagnostic and management advances, HFpEF still presents a diagnostic challenge and a paucity of therapies specifically aimed at enhancing survival and improving quality of life is still lacking. This review elucidates the diagnostic complexity of HFpEF, highlighting the use of both subjective and objective criteria within algorithmic frameworks. It also examines the significant impact of comorbidities on the progression of HFpEF. Additionally, we explore the latest evidence on targeting these comorbidities therapeutically, although the benefits to mortality are still limited.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/ccr/10.2174/011573403X318646240909072055
2024-09-19
2025-06-01

  • From This Site

    /content/journals/ccr/10.2174/011573403X318646240909072055
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. ClarkK.A. VelazquezE.J. Heart failure with preserved ejection fraction.JAMA2020324151506150810.1001/jama.2020.15566 33079136
     [Google Scholar]
  2. GladdenJ.D. LinkeW.A. RedfieldM.M. Heart failure with preserved ejection fraction.Pflugers Arch.201446661037105310.1007/s00424‑014‑1480‑8 24663384
     [Google Scholar]
  3. PfefferM.A. ShahA.M. BorlaugB.A. Heart failure with preserved ejection fraction in perspective.Circ. Res.2019124111598161710.1161/CIRCRESAHA.119.313572 31120821
     [Google Scholar]
  4. ShahS.J. KitzmanD.W. BorlaugB.A. Phenotype-specific treatment of heart failure with preserved ejection fraction.Circulation20161341739010.1161/CIRCULATIONAHA.116.021884 27358439
     [Google Scholar]
  5. BorlaugB.A. SharmaK. ShahS.J. HoJ.E. Heart failure with preserved ejection fraction.J. Am. Coll. Cardiol.202381181810183410.1016/j.jacc.2023.01.049 37137592
     [Google Scholar]
  6. DunlayS.M. RogerV.L. RedfieldM.M. Epidemiology of heart failure with preserved ejection fraction.Nat. Rev. Cardiol.2017141059160210.1038/nrcardio.2017.65 28492288
     [Google Scholar]
  7. GurwitzJ.H. MagidD.J. SmithD.H. Contemporary prevalence and correlates of incident heart failure with preserved ejection fraction.Am. J. Med.2013126539340010.1016/j.amjmed.2012.10.022 23499328
     [Google Scholar]
  8. SlivnickJ. LampertB.C. Hypertension and heart failure.Heart Fail. Clin.201915453154110.1016/j.hfc.2019.06.007 31472888
     [Google Scholar]
  9. OhG.C. ChoH.J. Blood pressure and heart failure.Clin. Hypertens.2020261110.1186/s40885‑019‑0132‑x 31908841
     [Google Scholar]
  10. TagawaH. RozichJ.D. TsutsuiH. Basis for increased microtubules in pressure-hypertrophied cardiocytes.Circulation19969361230124310.1161/01.CIR.93.6.1230 8653846
     [Google Scholar]
  11. ShahS.J. AistrupG.L. GuptaD.K. Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure.Am. J. Physiol. Heart Circ. Physiol.20143061H88H10010.1152/ajpheart.00642.2013 24186100
     [Google Scholar]
  12. BorbélyA. Falcao-PiresI. van HeerebeekL. Hypophosphorylation of the Stiff N2B titin isoform raises cardiomyocyte resting tension in failing human myocardium.Circ. Res.2009104678078610.1161/CIRCRESAHA.108.193326 19179657
     [Google Scholar]
  13. de SimoneG. GottdienerJ.S. ChinaliM. MaurerM.S. Left ventricular mass predicts heart failure not related to previous myocardial infarction: the Cardiovascular health study.Eur. Heart J.200829674174710.1093/eurheartj/ehm605 18204091
     [Google Scholar]
  14. HuangP.L. A comprehensive definition for metabolic syndrome.Dis. Model. Mech.200925-623123710.1242/dmm.001180 19407331
     [Google Scholar]
  15. ElluluM.S. PatimahI. Khaza’aiH. RahmatA. AbedY. Obesity and inflammation: The linking mechanism and the complications.Arch. Med. Sci.20174485186310.5114/aoms.2016.58928 28721154
     [Google Scholar]
  16. van de WouwJ. BroekhuizenM. SoropO. Chronic kidney disease as a risk factor for heart failure with preserved ejection fraction: a focus on microcirculatory factors and therapeutic targets.Front. Physiol.201910110810.3389/fphys.2019.01108 31551803
     [Google Scholar]
  17. PaulusW.J. TschöpeC. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J. Am. Coll. Cardiol.201362426327110.1016/j.jacc.2013.02.092 23684677
     [Google Scholar]
  18. ter MaatenJ.M. DammanK. VerhaarM.C. Connecting heart failure with preserved ejection fraction and renal dysfunction: the role of endothelial dysfunction and inflammation.Eur. J. Heart Fail.201618658859810.1002/ejhf.497 26861140
     [Google Scholar]
  19. GrundA. SinhaM.D. HaffnerD. Leifheit-NestlerM. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease—a pediatric perspective.Front Pediatr.2021970271910.3389/fped.2021.702719 34422725
     [Google Scholar]
  20. GoriM. SenniM. GuptaD.K. Association between renal function and cardiovascular structure and function in heart failure with preserved ejection fraction.Eur. Heart J.201435483442345110.1093/eurheartj/ehu254 24980489
     [Google Scholar]
  21. OktayA.A. RichJ.D. ShahS.J. The emerging epidemic of heart failure with preserved ejection fraction.Curr. Heart Fail. Rep.201310440141010.1007/s11897‑013‑0155‑7 24078336
     [Google Scholar]
  22. HwangS.J. MelenovskyV. BorlaugB.A. Implications of coronary artery disease in heart failure with preserved ejection fraction.J. Am. Coll. Cardiol.201463252817282710.1016/j.jacc.2014.03.034 24768876
     [Google Scholar]
  23. GuJ. PanJ. ZhangJ. WangC. Initial invasive or conservative strategy in heart failure with preserved ejection fraction and coronary artery disease.Front. Cardiovasc. Med.2022982224810.3389/fcvm.2022.822248 35369292
     [Google Scholar]
  24. SinhaA. RahmanH. WebbA. ShahA.M. PereraD. Untangling the pathophysiologic link between coronary microvascular dysfunction and heart failure with preserved ejection fraction.Eur. Heart J.202142434431444110.1093/eurheartj/ehab653 34529791
     [Google Scholar]
  25. Del BuonoM.G. MontoneR.A. CamilliM. Coronary microvascular dysfunction across the spectrum of cardiovascular diseases.J. Am. Coll. Cardiol.202178131352137110.1016/j.jacc.2021.07.042 34556322
     [Google Scholar]
  26. ZawadzkaM. GrabowskiM. Kapłon-CieślickaA. Phenotyping in heart failure with preserved ejection fraction: A key to find effective treatment.Adv. Clin. Exp. Med.202231101163117210.17219/acem/149728 35581935
     [Google Scholar]
  27. MosterdA. HoesA.W. Clinical epidemiology of heart failure.Heart20079391137114610.1136/hrt.2003.025270 17699180
     [Google Scholar]
  28. LienC.T. GillespieN.D. StruthersA.D. McMurdoM.E. Heart failure in frail elderly patients: diagnostic difficulties, co‐morbidities, polypharmacy and treatment dilemmas.Eur. J. Heart Fail.200241919810.1016/S1388‑9842(01)00200‑8 11812669
     [Google Scholar]
  29. VorilhonC. ChenafC. MulliezA. Heart failure prognosis and management in over-80-year-old patients: data from a French national observational retrospective cohort.Eur. J. Clin. Pharmacol.201571225126010.1007/s00228‑014‑1794‑7 25537794
     [Google Scholar]
  30. ZannadF. McMurrayJ.J. KrumH. Eplerenone in patients with systolic heart failure and mild symptoms.N. Engl. J. Med.20113641112110.1056/NEJMoa1009492 21073363
     [Google Scholar]
  31. SwedbergK. KomajdaM. BöhmM. Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study.Lancet2010376974487588510.1016/S0140‑6736(10)61198‑1 20801500
     [Google Scholar]
  32. SonaglioniA. LonatiC. TescaroL. Prevalence and clinical outcome of main echocardiographic and hemodynamic heart failure phenotypes in a population of hospitalized patients 70 years old and older.Aging Clin. Exp. Res.20223451081109410.1007/s40520‑021‑02025‑4 34988931
     [Google Scholar]
  33. KittlesonM.M. PanjrathG.S. AmancherlaK. 2023 ACC expert consensus decision pathway on management of heart failure with preserved ejection fraction.J. Am. Coll. Cardiol.202381181835187810.1016/j.jacc.2023.03.393 37137593
     [Google Scholar]
  34. ReddyY.N. KayeD.M. HandokoM.L. Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea.JAMA Cardiol.20227989189910.1001/jamacardio.2022.1916 35830183
     [Google Scholar]
  35. TomasoniD. AimoA. MerloM. Value of the HFA‐PEFF and H (2) FPEF scores in patients with heart failure and preserved ejection fraction caused by cardiac amyloidosis.Eur. J. Heart Fail.202224122374238610.1002/ejhf.2616 35855616
     [Google Scholar]
  36. PieskeB. TschöpeC. de BoerR.A. How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).Eur. Heart J.201940403297331710.1093/eurheartj/ehz641 31504452
     [Google Scholar]
  37. KhalidU. WruckL.M. QuibreraP.M. BNP and obesity in acute decompensated heart failure with preserved vs. reduced ejection fraction: The Atherosclerosis Risk in Communities Surveillance Study.Int. J. Cardiol.2017233616610.1016/j.ijcard.2017.01.130 28185703
     [Google Scholar]
  38. ObokataM. ReddyY.N. PislaruS.V. MelenovskyV. BorlaugB.A. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction.Circulation2017136161910.1161/CIRCULATIONAHA.116.026807 28381470
     [Google Scholar]
  39. BrubakerP.H. NicklasB.J. HoustonD.K. A randomized, controlled trial of resistance training added to caloric restriction plus aerobic exercise training in obese heart failure with preserved ejection fraction.Circ. Heart Fail.2023162e01016110.1161/CIRCHEARTFAILURE.122.010161 36314122
     [Google Scholar]
  40. WildingJ.P. BatterhamR.L. CalannaS. Once-weekly semaglutide in adults with overweight or obesity.N. Engl. J. Med.202138411989100210.1056/NEJMoa2032183 33567185
     [Google Scholar]
  41. JastreboffA.M. AronneL.J. AhmadN.N. Tirzepatide once weekly for the treatment of obesity.N. Engl. J. Med.2022387320521610.1056/NEJMoa2206038 35658024
     [Google Scholar]
  42. KosiborodM.N. AbildstrømS.Z. BorlaugB.A. Semaglutide in patients with heart failure with preserved ejection fraction and obesity.N. Engl. J. Med.2023389121069108410.1056/NEJMoa2306963 37622681
     [Google Scholar]
  43. OwanT.E. HodgeD.O. HergesR.M. JacobsenS.J. RogerV.L. RedfieldM.M. Trends in prevalence and outcome of heart failure with preserved ejection fraction.N. Engl. J. Med.2006355325125910.1056/NEJMoa052256 16855265
     [Google Scholar]
  44. WheltonP.K. CareyR.M. AronowW.S. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the american college of cardiology/american heart association task force on clinical practice guidelines.Hypertension20187161269132410.1161/HYP.0000000000000066 29133354
     [Google Scholar]
  45. LawM.R. MorrisJ.K. WaldN.J. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies.BMJ20093381b166510.1136/bmj.b1665 19454737
     [Google Scholar]
  46. InfeldM. WahlbergK. CiceroJ. Effect of personalized accelerated pacing on quality of life, physical activity, and atrial fibrillation in patients with preclinical and overt heart failure with preserved ejection fraction.JAMA Cardiol.20238321322110.1001/jamacardio.2022.5320 36723919
     [Google Scholar]
  47. YusufS. PfefferM.A. SwedbergK. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.Lancet2003362938677778110.1016/S0140‑6736(03)14285‑7 13678871
     [Google Scholar]
  48. ClelandJ.G.F. TenderaM. AdamusJ. FreemantleN. PolonskiL. TaylorJ. The perindopril in elderly people with chronic heart failure (PEP-CHF) study.Eur. Heart J.200627192338234510.1093/eurheartj/ehl250 16963472
     [Google Scholar]
  49. SolomonS.D. McMurrayJ.J. AnandI.S. Angiotensin–neprilysin inhibition in heart failure with preserved ejection fraction.N. Engl. J. Med.2019381171609162010.1056/NEJMoa1908655 31475794
     [Google Scholar]
  50. JacksonA.M. JhundP.S. AnandI.S. Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.Eur. Heart J.202142363741375210.1093/eurheartj/ehab499 34392331
     [Google Scholar]
  51. LedwidgeM. DoddJ.D. RyanF. Effect of sacubitril/valsartan vs valsartan on left atrial volume in patients with pre–heart failure with preserved ejection fraction.JAMA Cardiol.20238436637510.1001/jamacardio.2023.0065 36884247
     [Google Scholar]
  52. Biering-SørensenT. LassenM.C. ShahA. The effect of sacubitril/valsartan on left ventricular myocardial deformation in heart failure with preserved ejection fraction (paramount trial).J. Card. Fail.202329696897310.1016/j.cardfail.2023.03.019 37031887
     [Google Scholar]
  53. PittB. PfefferM.A. AssmannS.F. Spironolactone for heart failure with preserved ejection fraction.N. Engl. J. Med.2014370151383139210.1056/NEJMoa1313731 24716680
     [Google Scholar]
  54. PfefferM.A. ClaggettB. AssmannS.F. Regional variation in patients and outcomes in the treatment of preserved cardiac function heart failure with an aldosterone antagonist (topcat) trial.Circulation20151311344210.1161/CIRCULATIONAHA.114.013255 25406305
     [Google Scholar]
  55. DunlayS.M. GivertzM.M. AguilarD. Type 2 diabetes mellitus and heart failure: a scientific statement from the american heart association and the heart failure society of america: this statement does not represent an update of the 2017 acc/aha/hfsa heart failure guideline update.Circulation20191407e294e32410.1161/CIR.0000000000000691 31167558
     [Google Scholar]
  56. Pop-BusuiR. JanuzziJ.L. BruemmerD. Heart failure: An underappreciated complication of diabetes. A consensus report of the american diabetes association.Diabetes Care20224571670169010.2337/dci22‑0014 35796765
     [Google Scholar]
  57. AnkerS.D. ButlerJ. FilippatosG. Empagliflozin in heart failure with a preserved ejection fraction.N. Engl. J. Med.2021385161451146110.1056/NEJMoa2107038 34449189
     [Google Scholar]
  58. ButlerJ. FilippatosG. SiddiqiT.J. Effects of empagliflozin in women and men with heart failure and preserved ejection fraction.Circulation2022146141046105510.1161/CIRCULATIONAHA.122.059755 36098051
     [Google Scholar]
  59. SolomonS.D. McMurrayJ.J. ClaggettB. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.N. Engl. J. Med.2022387121089109810.1056/NEJMoa2206286 36027570
     [Google Scholar]
  60. KristensenS.L. RørthR. JhundP.S. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.Lancet Diabetes Endocrinol.201971077678510.1016/S2213‑8587(19)30249‑9 31422062
     [Google Scholar]
  61. SciricaB.M. BraunwaldE. RazI. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.Circulation2014130181579158810.1161/CIRCULATIONAHA.114.010389 25189213
     [Google Scholar]
  62. LipscombeL.L. GomesT. LévesqueL.E. HuxJ.E. JuurlinkD.N. AlterD.A. Thiazolidinediones and cardiovascular outcomes in older patients with diabetes.JAMA2007298222634264310.1001/jama.298.22.2634 18073359
     [Google Scholar]
  63. ZafrirB. LundL.H. LarocheC. Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the European Society of Cardiology Heart Failure Long-Term Registry.Eur. Heart J.201839484277428410.1093/eurheartj/ehy626 30325423
     [Google Scholar]
  64. ButtJ.H. KondoT. JhundP.S. Atrial fibrillation and dapagliflozin efficacy in patients with preserved or mildly reduced ejection fraction.J. Am. Coll. Cardiol.202280181705171710.1016/j.jacc.2022.08.718 36041668
     [Google Scholar]
  65. VaduganathanM. PicciniJ.P. CammA.J. Dronedarone for the treatment of atrial fibrillation with concomitant heart failure with preserved and mildly reduced ejection fraction: A post‐hoc analysis of the ATHENA trial.Eur. J. Heart Fail.20222461094110110.1002/ejhf.2487 35293087
     [Google Scholar]
  66. PackerD.L. MarkD.B. RobbR.A. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation.JAMA2019321131261127410.1001/jama.2019.0693 30874766
     [Google Scholar]
  67. PackerD.L. PicciniJ.P. MonahanK.H. Ablation versus drug therapy for atrial fibrillation in heart failure.Circulation2021143141377139010.1161/CIRCULATIONAHA.120.050991 33554614
     [Google Scholar]
  68. KirchhofP. CammA.J. GoetteA. Early rhythm-control therapy in patients with atrial fibrillation.N. Engl. J. Med.2020383141305131610.1056/NEJMoa2019422 32865375
     [Google Scholar]
  69. RilligA. MagnussenC. OzgaA.K. Early rhythm control therapy in patients with atrial fibrillation and heart failure.Circulation20211441184585810.1161/CIRCULATIONAHA.121.056323 34328366
     [Google Scholar]
  70. ChiengD. SugumarH. SeganL. Atrial fibrillation ablation for heart failure with preserved ejection fraction.JACC Heart Fail.202311664665810.1016/j.jchf.2023.01.008 36868916
     [Google Scholar]
  71. KotechaD. BuntingK.V. GillS.K. Effect of digoxin vs bisoprolol for heart rate control in atrial fibrillation on patient-reported quality of life.JAMA2020324242497250810.1001/jama.2020.23138 33351042
     [Google Scholar]
  72. LawtonJ.S. Tamis-HollandJ.E. BangaloreS. 2021 ACC/AHA/SCAI Guideline for coronary artery revascularization: executive summary: A report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation20221453e4e1710.1161/CIR.0000000000001039 34882436
     [Google Scholar]
  73. RedfieldM.M. AnstromK.J. LevineJ.A. Isosorbide mononitrate in heart failure with preserved ejection fraction.N. Engl. J. Med.2015373242314232410.1056/NEJMoa1510774 26549714
     [Google Scholar]
  74. HeidenreichP.A. BozkurtB. AguilarD. 2022 AHA/ACC/HFSA Guideline for the management of heart failure: A Report of the american college of cardiology/american heart association joint committee on clinical practice guidelines.Circulation202214518e895e103210.1161/CIR.0000000000001063 35363499
     [Google Scholar]
  75. KomajdaM. IsnardR. Cohen-SolalA. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo‐controlled trial.Eur. J. Heart Fail.201719111495150310.1002/ejhf.876 28462519
     [Google Scholar]
/content/journals/ccr/10.2174/011573403X318646240909072055
Loading
A Contemporary Review on Heart Failure with Preserved Ejection Fraction: Epidemiology, Diagnosis, and Management
Curr. Cardiol. Rev. 21, E1573403X318646 (2025); https://doi.org/10.2174/011573403X318646240909072055
/content/journals/ccr/10.2174/011573403X318646240909072055
/content/journals/ccr/10.2174/011573403X318646240909072055
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): algorithmic frameworks; cardiovascular; congestion; diastolic; Heart failure; metabolic syndrome

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test